This is a working overview of drug affinity complex, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-22 and is reviewed periodically as new material appears.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
== Signs and symptoms == The expected symptoms of Bornholm disease include fever, pleuritic chest pain, or epigastric abdominal pain that is frequently spasmodic. Bornholm associated chest pain is distinguished by attacks of severe pain in the lower chest, often on the right side. In a prior study, the episodes were shown to last five to ten minutes and then subside for thirty minutes. The pain is exacerbated by movement and makes walking and breathing more difficult. Patients have found relief from the pain by lying still for a brief period of time. The slightest movement of the rib cage causes a sharp increase in pain, which makes it difficult to breathe, although it generally passes off before any actual harm occurs. The attacks are unpredictable and strike "out of the blue" with a feeling like an iron grip around the rib cage. The colloquial names for the disease, such as the devil's grip, (see "other names" below) reflect this symptom. Bornholm disease is a clinical diagnosis that uses the spasmodic pain, fever, and relapses to distinguish the illness from other potential causes of pain such as appendicitis or myocardial infarction. Tachycardia and arrhythmias have been found with Bornholm disease by using an electrocardiogram (ECG). Murmurs, rubs, and pericardial effusions have been detected on physical examination. Maculopapular rashes can also be present with Bornholm disease
By 2015, even at 90 years old, Mahathir remained sharp and combative. He repeatedly called for prime minister Najib Razak to resign over the 1Malaysia Development Berhad scandal (1MDB). On 30 August 2015, he and Siti Hasmah attended the Bersih 4 rally, a mass protest organised in response to the scandal. In 2016, Mahathir chaired the Malaysian Citizens' Declaration, which brought together several political figures and non-governmental organisations in calling for Najib's resignation. In this declaration, Mahathir listed 37 points. Later, the Citizens' Declaration reached one million signatures in May of the same year. In the 2016 Sungai Besar by-election, he supported Amanah and other Pakatan Harapan leaders, lending his influence to the opposition coalition. Mahathir left UMNO in 2016, and formed Parti Pribumi Bersatu Malaysia (BERSATU). The new party was officially registered on 9 September 2016, and Mahathir became its chairman. By 2017, he had officially joined the opposition coalition Pakatan Harapan. Negotiations then took place between different factions of the coalition for Mahathir to become the chairman and prime ministerial candidate. He assumed the position of chairman on 14 July 2017, despite reservations from supporters of Anwar Ibrahim, who could not contest in polls himself while imprisoned. In 2016, Mahathir had his police outriders withdrawn after his privileges were revoked due to his participation in anti-government events.
=== Alternative classifications === There is an increasing discussion about whether the differences between species adequately represents the variability found within the genus Cannabis. There are five chemotaxonomic types of cannabis: one with high levels of THC, one which is more fibrous and has higher levels of CBD, one that is an intermediate between the two, another one with high levels of cannabigerol (CBG), and the last one almost without cannabinoids. There has also been a recent movement to characterize strains based on their reported subjective effects.
Sources: en.wikipedia.org
On the other hand, basement membrane along the mature mammary ducts is thicker, with strong adhesion to epithelial cells via binding to integrin and non-integrin receptors. When side branches develop, it is a much more "pushing-forward" working process including extending through myoepithelial cells, degrading basement membrane and then invading into a periductal layer of fibrous stromal tissue. Degraded basement membrane fragments (laminin-5) roles to lead the way of mammary epithelial cells migration. Whereas, laminin-1 interacts with non-integrin receptor dystroglycan negatively regulates this side branching process in case of cancer. These complex "Yin-yang" balancing crosstalks between mammary ECM and epithelial cells "instruct" healthy mammary gland development until adult. There is preliminary evidence that soybean intake mildly stimulates the breast glands in pre- and postmenopausal women.
=== Direct analysis of biotransformations === An adaptation of DESI is used to analyze enzyme-triggered chemical reactions, known as biotransformations, in enzymes and their products. Coupled with high-resolution mass spectrometry, this procedure, known as DiBT-MS, can analyze a substrate 10-10,000 times quicker than LC-MS. DESI specifically can analyze the products in situ, removing the need for high solvent usage and creating these quicker analysis times.
(1933), first African-American basketball player to be selected as All-American Alfred Skrobisch (1933), Olympic fencer Cliff Montgomery (1934), led the Columbia Lions football team to victory in the Rose Bowl John O'Brien (1938), basketball player for the Akron Wingfoots Ben Johnson (1938), sprinter who rivaled Jesse Owens Sid Luckman (1939), NFL Hall of Fame Chicago Bears quarterback Ken Germann (1943), football coach, athletic director of Columbia University, and former Southern Conference commissioner Paul Governali (1943), football player for the Boston Yanks and New York Giants Walt Budko (1948), basketball player for Baltimore Bullets and Philadelphia Warriors Bruce Gehrke (1948), football player for New York Giants Bill Swiacki (1948), player for New York Giants, member of the College Football Hall of Fame Lou Kusserow (1949), football player for Hamilton Tiger-Cats and New York Yanks John Azary (1951), basketball player, recipient of the Haggerty Award Jack Molinas (1953), NBA player for the Fort Wayne Pistons Jack Rohan (1953), head coach of the Columbia Lions men's basketball team 1961–1974, and 1990–1995 George Shaw (1953), Olympic triple jumper Richard Ballantine* (1967), cyclist and cycling advocate; son of Ian Ballantine '38 of Ballantine Books James Margolis (1958), Olympic fencer James Melcher (1961), Olympian fencer, president of Fencers Club and hedge fund manager Robert Contiguglia (1963), soccer player, former president of the United States Soccer Federation Peter Salzberg (1964), head coach of Vermont Catamounts men's basketball 1972–1981 Archie Roberts (1965), former football player for the Miami Dolphins and cardiac surgeon Jim McMillian (1968), NBA player for the Los Angeles Lakers, Buffalo Braves, New York Knicks and Portland Trail Blazers Dave Newmark (1968), NBA player for the Chicago Bulls; also played for Israeli team Hapoel Tel Aviv B.C. Marty Domres (1969), football player for San Diego Chargers and Baltimore Colts Heyward Dotson (1970), basketball player George Starke (1971), offensive lineman for the Washington Redskins Henry Bunis (1975), two-time All-American tennis player, runner-up in 1977 Chilean Open Rick Fagel (1975), professional tennis player Vitas Gerulaitis* (1975), champion tennis player Thomas Losonczy (1975), Olympic fencer, winner of the Congressional Gold Medal Alton Byrd (1979), basketball player Eric Fromm (1980), tennis player John Witkowski (1983), football player for Detroit Lions and Houston Oilers Gene Larkin (1984), member of the Minnesota Twins 1987 and 1991 World Series championship teams Amr Aly (1985), soccer player who won the Hermann Trophy as the top college player of the year 1984; member of the 1984 U.S. Olympic Soccer Team and indoor soccer team Los Angeles Lazers Stephen Trevor (1986), Olympic fencer Kyra Tirana Barry (1987), team leader for U.S. women's national wrestling team Caitlin Bilodeaux (1987), Olympic fencer Howard Endelman (1987), tennis player Phil Williamson (1987), tennis player for Antigua and Barbuda Bob Cottingham (1988), Olympic fencer Jon Normile (1989), Olympic fencer Frank Seminara (1989), Major League Baseball pitcher for the San Diego Padres and the New York Mets Tom Auth (1990), Olympic rower Christine Vardaros (1991), professional cyclist Ann Marsh (1994), Olympic fencer Ríkharður Daðason (1996), Icelandic soccer player Marcellus Wiley (1997), football player for the Buffalo Bills, San Diego Chargers and Dallas Cowboys Dan Kellner (1998), fencer Pellegrino Matarazzo (1999), head coach of VfB Stuttgart Matt Napoleon (1999), Olympic soccer goalkeeper Cristina Teuscher (2000), Olympic gold medalist swimmer Jedediah Dupree (2001), NCAA Champion fencer Veljko Urošević (2003), Serbian Olympic rower Fernando Perez (2004), outfielder for the Tampa Bay Rays Jeremiah Boswell (2005), professional basketball player for BC Sliven, KK Strumica, and KK Torus Delilah DiCrescenzo (2005), long-distance runner, inspiration and subject of the Grammy-nominated song Hey There Delilah Michael Quarshie (2005), Finnish American football player who played for the Oakland Raiders and Frankfurt Galaxy Lisa Nemec (2006), Croatian long-distance runner Miloš Tomić (2006), Serbian Olympic rower Erison Hurtault (2007), Dominican sprinter James Leighman Williams (2007), fencer who won silver in the 2008 Summer Olympics Emily Jacobson (2008), fencer İhsan Emre Vural (2008), Turkish rower for Galatasaray S.K. Sherif Farrag (2009), Egyptian-American Olympic fencer Nicholas la Cava (2009), Olympic rower Jeff Spear (2010), Olympic fencer Daria Schneider (2010), fencer Jeff Adams (2011), Houston Texans offensive tackle Nicole Ross (2011), Olympic fencer Isadora Cerullo (2013), Brazilian-American Olympic rugby player Katie Meili (2013), Olympic swimmer, Pan American Games and 2016 Summer Olympics gold medalist Josh Martin (2013), Kansas City Chiefs linebacker John Gregorek Jr. (2014), middle-distance runner David Najem (2014), American soccer player for New Mexico United and the Afghanistan national football team Nadia Eke (2015), Ghanaian triple jumper, African Championships gold medalist in 2016 Kristine Musademba (2015), figure skater Max Schnur (2015), tennis player playing on the ATP Challenger Tour Nzingha Prescod (2015), Olympic fencer Ramit Tandon (2015), professional squash player Jakub Buczek (2016), Canadian Olympic rower Sasha DiGiulian (2016), world champion climber Jacqueline Dubrovich (2016), Olympic fencer Maodo Lô (2016), German basketball player for Brose Bamberg Robb Paller (2016), American-Israeli Olympic baseball player Jeff Coby (2017), American basketball player for Xuventude Baloncesto Cameron Nizialek (2017), football player for Atlanta Falcons Akua Obeng-Akrofi (2018), Ghanaian sprinter Charlotte Buck (2018), Olympic rower Osama Khalifa (2018), #1 ranked college squash player in the U.S. for the 2016–17 season Camille Zimmerman (2018), American basketball player for Norrköping Dolphins Yasmeen Al-Dabbagh (2019), Saudi Arabian sprinter Jessica Antiles (2019), swimmer who won silver and bronze medals in the 2017 Maccabiah Games Dylan Castanheira (2019), soccer player, goalkeeper for Fort Lauderdale CF Sophie Whitehouse (2019), goalkeeper for Republic of Ireland women's national football team Mike Smith (2020), basketball player Anthony Jackie Tang (2020), Hong Kong tennis player John Tanguay (2020), rower who won a silver medal in the 2020 Summer Paralympics Dylan Geick* (2021), wrestler and internet personality Velavan Senthilkumar (2021), British Junior Open Squash champion and Asian Junior Squash champion Nastasya Generalova (2023), gymnast and model Olivia Giaccio (2024), Olympic freestyle skier Evita Griskenas (2024), rhythmic gymnast Camden Pulkinen (2024), figure skater Abbey Hsu (2024), basketball player
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.